News & Updates

Among patients who received 6 months of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), switching to a single antiplatelet therapy (SAPT) regimen for another 6 months resulted in less gastrointestinal (GI) injury than continuing DAPT, results of the OPT-PEACE trial showed.

The anti–interleukin (IL)-4/-13 antibody dupilumab led to sustained improvements across symptomatic, histologic, and endoscopic measures of eosinophilic oesophagitis (EoE) out to 52 weeks, according to additional data from the LIBERTY EoE TREET trial presented at ACG 2021.

Eosinophilic esophagitis patients are likely to experience histological relapse despite ongoing treatment with swallowed topical corticosteroid (STC), but relapse occurs later with high- than with low-dose STC without any increase in side effects, a study has found.

In the treatment of patients with cirrhosis and hepatic encephalopathy (HE), the ammonia scavenger ornithine phenylacetate is safe and similar to placebo in terms of time to clinical improvement, according to data from a phase IIb trial.

An energy-restricted Mediterranean diet combined with physical activity (PA) results in better high-density lipoprotein (HDL) triglyceride metabolism compared with a nonrestrictive diet without PA in older adults with metabolic syndrome (MetS), reports a study.

Vonoprazan-containing triple- or dual-therapy regimens are superior to lansoprazole triple therapy in eradicating Helicobacter pylori (H. pylori), according to the phase III pHalcon-HP study presented at ACG 2021.

People with unrestrained eating behaviour are at higher risk of gastrointestinal (GI) tract cancers, reveals a recent study.